Genomed Spólka Akcyjna (WSE:GEN)

Market Cap	36.47M
Revenue (ttm)	25.14M
Net Income (ttm)	2.20M
Shares Out	1.32M
EPS (ttm)	n/a
PE Ratio	16.58
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	95
Average Volume	15
Open	27.20
Previous Close	27.00
Day's Range	27.20 - 27.60
52-Week Range	23.00 - 29.00
Beta	-0.12
RSI	76.46
Earnings Date	Nov 13, 2025

About Genomed Spólka Akcyjna

Genomed Spólka Akcyjna provides DNA sequencing and analysis, and diagnostics of congenital diseases in Poland. It develops molecular diagnostics based on DNA sequencing for the application of prophylactics and treatment, such as replacement or gene therapy. The company’s diagnostic services include DNA isolation, PCR amplification and Sanger sequencing of DNA regions, the comparison of the sequences, and the interpretation of the results by diagnosticians. In addition, it provides various types of DNA sequence analysis, including polymorphism a...

• Industry: In Vitro and In Vivo Diagnostic Substances
• Founded: 2007
• Employees: 54
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: GEN

Financial Performance

In 2024, Genomed Spólka Akcyjna's revenue was 23.01 million, an increase of 2.34% compared to the previous year's 22.48 million. Earnings were 1.11 million, an increase of 19.32%.